vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and Hippo Holdings Inc. (HIPO). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $120.4M, roughly 1.7× Hippo Holdings Inc.). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs 5.0%, a 3.3% gap on every dollar of revenue. On growth, Hippo Holdings Inc. posted the faster year-over-year revenue change (18.2% vs 12.9%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $9.1M). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs 18.9%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.
COLL vs HIPO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $120.4M |
| Net Profit | $17.0M | $6.0M |
| Gross Margin | 62.5% | — |
| Operating Margin | 29.6% | 5.6% |
| Net Margin | 8.3% | 5.0% |
| Revenue YoY | 12.9% | 18.2% |
| Net Profit YoY | 35.3% | -86.4% |
| EPS (diluted) | $0.48 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.4M | $120.4M | ||
| Q3 25 | $209.4M | $120.6M | ||
| Q2 25 | $188.0M | $117.3M | ||
| Q1 25 | $177.8M | $110.3M | ||
| Q4 24 | $181.9M | $101.9M | ||
| Q3 24 | $159.3M | $95.5M | ||
| Q2 24 | $145.3M | $89.6M | ||
| Q1 24 | $144.9M | $85.1M |
| Q4 25 | $17.0M | $6.0M | ||
| Q3 25 | $31.5M | $98.1M | ||
| Q2 25 | $12.0M | $1.3M | ||
| Q1 25 | $2.4M | $-47.7M | ||
| Q4 24 | $12.5M | $44.2M | ||
| Q3 24 | $9.3M | $-8.5M | ||
| Q2 24 | $19.6M | $-40.5M | ||
| Q1 24 | $27.7M | $-35.7M |
| Q4 25 | 62.5% | — | ||
| Q3 25 | 61.7% | — | ||
| Q2 25 | 57.7% | — | ||
| Q1 25 | 54.8% | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 62.5% | — | ||
| Q1 24 | 63.1% | — |
| Q4 25 | 29.6% | 5.6% | ||
| Q3 25 | 29.7% | 81.3% | ||
| Q2 25 | 18.7% | 3.4% | ||
| Q1 25 | 12.2% | -41.3% | ||
| Q4 24 | 20.9% | 46.3% | ||
| Q3 24 | 21.9% | -5.4% | ||
| Q2 24 | 32.7% | -40.7% | ||
| Q1 24 | 34.1% | -38.7% |
| Q4 25 | 8.3% | 5.0% | ||
| Q3 25 | 15.0% | 81.3% | ||
| Q2 25 | 6.4% | 1.1% | ||
| Q1 25 | 1.4% | -43.2% | ||
| Q4 24 | 6.9% | 43.4% | ||
| Q3 24 | 5.9% | -8.9% | ||
| Q2 24 | 13.5% | -45.2% | ||
| Q1 24 | 19.1% | -42.0% |
| Q4 25 | $0.48 | $0.31 | ||
| Q3 25 | $0.84 | $3.77 | ||
| Q2 25 | $0.34 | $0.05 | ||
| Q1 25 | $0.07 | $-1.91 | ||
| Q4 24 | $0.36 | $1.81 | ||
| Q3 24 | $0.27 | $-0.34 | ||
| Q2 24 | $0.52 | $-1.64 | ||
| Q1 24 | $0.71 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $218.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $436.1M |
| Total Assets | $1.7B | $1.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $386.7M | $218.3M | ||
| Q3 25 | $285.9M | $247.7M | ||
| Q2 25 | $222.2M | $198.9M | ||
| Q1 25 | $197.8M | $140.9M | ||
| Q4 24 | $162.8M | $197.6M | ||
| Q3 24 | $120.0M | $191.2M | ||
| Q2 24 | $271.6M | $175.9M | ||
| Q1 24 | $318.0M | $223.4M |
| Q4 25 | $301.7M | $436.1M | ||
| Q3 25 | $274.8M | $421.5M | ||
| Q2 25 | $232.2M | $332.5M | ||
| Q1 25 | $234.4M | $322.8M | ||
| Q4 24 | $228.8M | $362.1M | ||
| Q3 24 | $234.3M | $326.4M | ||
| Q2 24 | $216.6M | $322.6M | ||
| Q1 24 | $222.2M | $351.2M |
| Q4 25 | $1.7B | $1.9B | ||
| Q3 25 | $1.6B | $1.9B | ||
| Q2 25 | $1.6B | $1.7B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.7B | $1.5B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.1B | $1.5B | ||
| Q1 24 | $1.1B | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $9.2M |
| Free Cash FlowOCF − Capex | $122.4M | $9.1M |
| FCF MarginFCF / Revenue | 59.6% | 7.6% |
| Capex IntensityCapex / Revenue | 0.3% | 0.1% |
| Cash ConversionOCF / Net Profit | 7.25× | 1.53× |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | $14.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.0M | $9.2M | ||
| Q3 25 | $78.4M | $16.9M | ||
| Q2 25 | $72.4M | $24.7M | ||
| Q1 25 | $55.4M | $-35.6M | ||
| Q4 24 | $84.6M | $47.5M | ||
| Q3 24 | $-9.0M | $46.8M | ||
| Q2 24 | $67.4M | $-10.6M | ||
| Q1 24 | $61.9M | $17.7M |
| Q4 25 | $122.4M | $9.1M | ||
| Q3 25 | $78.3M | $16.8M | ||
| Q2 25 | $72.4M | $24.6M | ||
| Q1 25 | $54.6M | $-35.7M | ||
| Q4 24 | $84.1M | $47.2M | ||
| Q3 24 | $-9.2M | — | ||
| Q2 24 | $67.1M | $-10.7M | ||
| Q1 24 | $61.4M | $17.6M |
| Q4 25 | 59.6% | 7.6% | ||
| Q3 25 | 37.4% | 13.9% | ||
| Q2 25 | 38.5% | 21.0% | ||
| Q1 25 | 30.7% | -32.4% | ||
| Q4 24 | 46.2% | 46.3% | ||
| Q3 24 | -5.8% | — | ||
| Q2 24 | 46.2% | -11.9% | ||
| Q1 24 | 42.3% | 20.7% |
| Q4 25 | 0.3% | 0.1% | ||
| Q3 25 | 0.1% | 0.1% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.4% | 0.1% | ||
| Q4 24 | 0.3% | 0.3% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 0.2% | 0.1% | ||
| Q1 24 | 0.4% | 0.1% |
| Q4 25 | 7.25× | 1.53× | ||
| Q3 25 | 2.49× | 0.17× | ||
| Q2 25 | 6.05× | 19.00× | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | 1.07× | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | — | ||
| Q1 24 | 2.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
